Status:
COMPLETED
Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus
Lead Sponsor:
Tehran University of Medical Sciences
Collaborating Sponsors:
RojanPharma Pharmaceutical Company
Conditions:
Hepatitis C Virus Infection, Response to Therapy of
Human Immunodeficiency Virus
Eligibility:
All Genders
12-75 years
Phase:
PHASE3
Brief Summary
In a multi-center study 200 patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) will be treated with a fixed-dose combination pill combined of 400 mg sofosbuvir an...
Detailed Description
To achieve the goal of elimination of hepatitis C in 2030 as set forward by the world health organization (WHO) a main group requiring treatment are subjects co-infected with HIV. These subjects offer...
Eligibility Criteria
Inclusion
- Positive qualitative hepatitis C virus RNA test on two occasions at least 6 months apart
- Positive human immunodeficiency virus test
Exclusion
- Heart rate \< 50/min,
- Taking amiodarone
- Renal failure
Key Trial Info
Start Date :
January 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2018
Estimated Enrollment :
232 Patients enrolled
Trial Details
Trial ID
NCT03369327
Start Date
January 1 2017
End Date
December 1 2018
Last Update
February 20 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Shariati Hospital
Tehran, Iran, 14117
2
Emam Hospital
Tehran, Iran